Answers are grounded in this paper and cite their sources.
INTRODUCTION: Lipinski's Rule of Five (Ro5) has long framed the characteristics of orally administered drugs; however, many clinically relevant targets, particularly protein-protein interactions and other complex interfaces, require compounds operating in chemical space beyond this rule. Understanding how these drugs surpass classical thresholds while maintaining efficacy and pharmacokinetics is a fundamental aspect of modern drug discovery. AREAS COVERED: This narrative review is based on a literature using PubMed/Medline between 2016 and 2026. The DrugBank database was also used as an illustrative, retrospective case study to examine how literature-derived bRo5 principles are reflected in approved drugs. The review focuses on five key modalities: optimized small molecules, natural products, peptides/peptidomimetics, macrocycles, and proteolysis-targeting chimeras. EXPERT OPINION: Approved bRo5 drugs illustrate that the classic Ro5 should be reconsidered as a context-dependent guideline rather than a universal filter. In the authors' view, future discovery campaigns targeting complex biological targets should move away from rigid thresholds and adopt a deliberate bRo5 design, prioritizing control of hydrogen bonds, 3D shape, and chameleonicity over simple compliance scores. Integrating high-quality structural data with Artificial Intelligence-driven physics-based models may be particularly valuable for rationally expanding the bRo5 chemical space, reducing reliance on empirical trial-and-error, and addressing inaccessible targets to conventional small molecules.
No takes yet. Share an insight, caveat, or question.
Blanes‐Mira et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: